Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes: A phase 2 randomized controlled trial.

Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y, Qiu W, Ma Q, Liu Z, Wang Y, Deng H, Du H, Han-Zhang H, Qian L

Med (New York, N.Y.)23 Mar 2026Cited by 3 (Europe PMC)

PMID41875890DOI10.1016/j.medj.2026.101063PepBankPUB-41875890

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with a BMI of 30 or more and no diabetes, mazdutide 9 mg reduced body weight more than placebo at week 24 (treatment difference -14.58%, p < 0.0001).
In plain wordsIn Chinese adults with obesity and no diabetes, mazdutide 9 mg lowered body weight more than placebo after 24 weeks.
Peptide
Mazdutide
Outcome
DecreasePercent body weight change at week 24
Study
n = 80
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg · 24 weeksAs given in this study (human).
Measurements
Body weight change
−12.78%
mazdutide 9 mg
Body weight change
1.8%
placebo
Treatment difference in body weight
−14.58%
mazdutide 9 mg vs placebo
Source sentences
Summary
At week 24, the mean percentage change in weight from baseline was -12.78% with mazdutide 9 mg and 1.80% with placebo (treatment difference: -14.58% [95% confidence interval (CI) -18.00, -11.16], p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589001
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with a BMI of 30 or more and no diabetes, 81.7% of those on mazdutide 9 mg lost at least 5% of weight, and none on placebo did.
In plain wordsIn Chinese adults with obesity and no diabetes, most people on mazdutide 9 mg lost at least 5% of weight, and none on placebo did.
Peptide
Mazdutide
Outcome
IncreaseProportion with weight reduction of at least 5%
Study
n = 80
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg · 24 weeksAs given in this study (human).
Measurements
Proportion with weight reduction of 5% or more
81.7%
mazdutide 9 mg
Proportion with weight reduction of 5% or more
0%
placebo
Source sentences
Summary
Weight reduction ≥5% was achieved by 81.7% of participants with mazdutide after 24-week treatment, while no participants with placebo achieved this threshold.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589002
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with a BMI of 30 or more and no diabetes, mazdutide 9 mg was associated with greater improvements in cardiometabolic risk factors than placebo.
In plain wordsIn Chinese adults with obesity and no diabetes, mazdutide 9 mg was linked to greater improvements in heart and metabolic risk factors than placebo.
Peptide
Mazdutide
Outcome
Direction not reportedCardiometabolic risk factors
Study
n = 80
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
9 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
Mazdutide treatment was associated with greater improvements in cardiometabolic risk factors vs. placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589003
04HumanRandomized controlled trialSafety outcome
In Chinese adults with a BMI of 30 or more and no diabetes, nausea occurred more often with mazdutide 9 mg than with placebo (50.0% versus 0%).
In plain wordsIn Chinese adults with obesity and no diabetes, nausea was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseNausea
Study
n = 80
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · 24 weeksAs given in this study (human).
Measurements
Nausea incidence
50%
mazdutide 9 mg
Nausea incidence
0%
placebo
Source sentences
Summary
The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589004
05HumanRandomized controlled trialSafety outcome
In Chinese adults with a BMI of 30 or more and no diabetes, diarrhea occurred more often with mazdutide 9 mg than with placebo (38.3% versus 10.0%).
In plain wordsIn Chinese adults with obesity and no diabetes, diarrhea was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseDiarrhea
Study
n = 80
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · 24 weeksAs given in this study (human).
Measurements
Diarrhea incidence
38.3%
mazdutide 9 mg
Diarrhea incidence
10%
placebo
Source sentences
Summary
The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589005
06HumanRandomized controlled trialSafety outcome
In Chinese adults with a BMI of 30 or more and no diabetes, vomiting occurred more often with mazdutide 9 mg than with placebo (36.7% versus 10.0%).
In plain wordsIn Chinese adults with obesity and no diabetes, vomiting was more common with mazdutide 9 mg than with placebo.
Peptide
Mazdutide
Outcome
IncreaseVomiting
Study
n = 80
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · 24 weeksAs given in this study (human).
Measurements
Vomiting incidence
36.7%
mazdutide 9 mg
Vomiting incidence
10%
placebo
Source sentences
Summary
The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks.
Summary · context
Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20).
Report a problemFND-4187589006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04904913

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Innovent Biologics (Suzhou) Co. Ltd.n = 3288 Jun 2021 to 6 Dec 2023

Overweight/ Obesity

Trial page ClinicalTrials.govUpdated 17 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.